BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
VSTM upcoming catalysts
Verastem, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 0 FDA event(s). Subscribe to VSTM (.ics).
Drugs: avutometinib, defactinib, gemcitabine, nab-paclitaxel, adagrasib, sotorasib
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-08-31 est. | P1/P2 | Verastem, Inc. VSTM | NCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neopla | active not recruiting | 40 |
| 2026-06-15 | P1/P2 | Verastem, Inc. VSTM | NCT05375994 Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer; KRAS Activating Mutation; Advanced Cancer; Metastatic Cancer; Malignant | completed | 12 |
| 2026-06 est. | P1/P2 | Verastem, Inc. VSTM | NCT05074810 Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients | Non Small Cell Lung Cancer; KRAS Activating Mutation | active not recruiting | 153 |
| 2025-12 est. | P2 | Verastem, Inc. VSTM | NCT06682572 A Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients | Low Grade Serous Ovarian Cancer; Ovarian Cancer | active not recruiting | 16 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.